FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit

FDA Reverses Stance on Ebvallo's Trial Design After Leadership Change

The FDA has reversed its previous rejections of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo, for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (PTLD) in children aged two and older. Following a positive Type A meeting and the departure of CBER Director Vinay Prasad, the agency now agrees that a single-arm study with an appropriate historical control can support approval. The partners plan to resubmit their Biologics License Application with updated data from the pivotal Phase 3 ALLELE study, leading to a significant surge in Atara's stock.

• The FDA's agreement to accept a single-arm study with a historical control for Ebvallo's approval marks a significant shift from its prior rejections, which cited trial design insufficiency. This decision, reached during a Type A meeting, provides a clear regulatory pathway for the cell therapy, allowing Atara and Pierre Fabre to proceed with resubmission.
• The FDA's change of stance occurred just one week after the departure of controversial CBER Director Vinay Prasad. This timing has been highlighted by former FDA staff and analysts as potentially influential, suggesting that the leadership transition may have contributed to the agency's re-evaluation of Ebvallo's registrational trial.
• Atara and Pierre Fabre intend to resubmit their BLA for Ebvallo, targeting children aged two years and older with Epstein-Barr virus-positive PTLD. The resubmission will include an updated dataset with additional patients and longer follow-up time from the pivotal Phase 3 ALLELE study, with a further regulatory update anticipated in the third quarter.

Addressing the Critical Unmet Needs in EBV+ PTLD

Recent advances have highlighted significant gaps in PTLD management, particularly for high-risk populations with limited therapeutic options. The landscape reveals critical unmet needs spanning from pediatric survivors to complex transplant scenarios requiring novel immunotherapeutic approaches.

Key Populations Being Targeted:

• Relapsed or refractory EBV-positive PTLD patients following HSCT or SOT - representing an ultra-rare disease with poor survival after failure of initial therapy and few treatment options, now addressed by tabelecleucel as the first off-the-shelf, allogeneic, EBV-specific T-cell immunotherapy

• Pediatric PTLD survivors (0-18 years old) - little is known regarding late effects in survivors, which may influence treatment decisions regarding chemotherapy toxicities, with studies showing 82% experiencing grade 3 toxicity or higher regardless of chemotherapy exposure

• Children with post-SOT monomorphic PTLD (mPTLD) - balancing risks of infection, mPTLD progression and organ rejection is challenging, and the intensity of therapy required by individual patients is not defined

• Lung transplant recipients treated with belatacept - the epidemiology of infections in belatacept-treated LuTRs has not been systematically evaluated, with 6% developing EBV+ PTLD and 20% of seropositive patients developing CMV infections

• Solid organ transplant recipients receiving CAR T-cell therapy for PTLD - no established consensus regarding optimal maintenance immunosuppressive strategy post-CAR T-cell therapy due to heterogeneous nature of PTLD and scarcity of clinical trial data

Critical Unmet Therapeutic Needs:

• Defining optimal treatment intensity for individual pediatric mPTLD patients - although increasing evidence supports stepwise escalation through reduction in immunosuppression to rituximab monotherapy and low-dose chemo-immunotherapy, many centers still use B-cell non-Hodgkin lymphoma protocols

• Understanding infection risks in belatacept-treated LuTRs - multicenter collaborations needed as patients commonly developed CMV infections, EBV+ PTLD, and bacterial infections in first year after belatacept initiation

• Balancing competing risks in CAR T-cell therapy for PTLD - clinicians must balance allograft rejection risk, potential for maintenance immunosuppression to diminish CAR T-cell efficacy, and increased infection risk requiring individualized approaches

• Characterizing molecular profiles of PTLD DLBCL - most understanding extrapolated from studies in non-PTLD DLBCL, with T/NK-cell PTLD showing particularly poor outcomes with 100% of patients progressing or relapsing and subsequently dying of disease

Prognostic Factors and Risk Stratification:

• Early-onset PTLD (≤150 days) identified as prognostic factor for lower overall survival in allo-HSCT group, with median onset markedly shorter after allo-HSCT (2 months) versus SOT (99 months)

• Performance status indicators - ECOG >2 identified as prognostic factor for lower overall survival in SOT group, with overall response rates lower in allo-HSCT (67%) compared to SOT group (100%)

The ALLELE Study Design Supporting Ebvallo's Resubmission

Recent clinical trials for PTLD have employed diverse study designs ranging from prospective phase 2 trials to large retrospective cohort studies, with endpoints focused on response rates, survival outcomes, and safety profiles. The most significant recent trial was the TIDaL study, which investigated risk-stratified therapy, while several retrospective analyses have provided long-term outcome data across different transplant populations.

Ebvallo's Position in the PTLD Therapeutic Landscape

Several bispecific T-cell engaging antibodies are being evaluated for B-cell lymphomas using similar mechanisms of action to Ebvallo. These agents employ CD3-targeting strategies to recruit T-cells against tumor cells, with most trials utilizing single-arm study designs to establish efficacy in heavily pretreated patient populations.

Ebvallo's FDA Nod: Reshaping EBV-PTLD Treatment and Regulatory Pathways

The recent FDA reversal regarding Ebvallo (tabelecleucel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV-PTLD) marks a pivotal moment for patients and the cell therapy landscape. This decision, following a positive Type A meeting, signals a significant shift in regulatory perspective, particularly the acceptance of a single-arm study with historical controls for an ultra-rare disease. For patients suffering from relapsed or refractory EBV-PTLD, a life-threatening complication with limited treatment options and poor prognosis, this represents a beacon of hope.

Tabelecleucel is an allogeneic, off-the-shelf EBV-specific T-cell immunotherapy designed to restore virus-specific immunity. Clinical data from the Phase 3 ALLELE study demonstrated significant clinical benefit and an overall survival advantage compared to current treatments in this challenging patient population. Importantly, the therapy has shown a favorable safety profile, with no reports of common T-cell therapy toxicities like graft-versus-host disease, cytokine release syndrome, or neurotoxicity, which is crucial for immunocompromised transplant recipients.

However, as with any novel therapy, considerations remain. While the ALLELE study provided robust evidence, real-world experience is still accumulating, and some data suggest that a notable proportion of patients may still experience relapse or progression, necessitating ongoing clinical vigilance and potential subsequent therapies. Furthermore, the ultra-rare nature of EBV-PTLD, while justifying accelerated regulatory pathways, presents inherent commercial challenges in terms of patient identification and market access. The dynamic field of adoptive cell immunotherapy also means that future competition from emerging CAR T-cell therapies and other targeted approaches for EBV-associated diseases could evolve. Nevertheless, this FDA approval, building on its European authorization, firmly establishes tabelecleucel as a critical new tool in the fight against EBV-driven malignancies and validates the potential of allogeneic T-cell therapies.